CASI Pharmaceuticals, Inc. (CASIF)
CASIF is quoted over the counter, not listed on an exchange. CASI Pharmaceuticals, Inc. files reports with the SEC; the numbers below come from SEC filings and from daily closes, each with its source.
Closes: Yahoo Finance daily closes, last bar 2026-11-16.
Profile
| Field | Value |
|---|---|
| Ticker | CASIF, quoted over the counter |
| SEC CIK | 0001962738 |
| OTC Markets tier | OTCQB (price source, 2026-11-13) |
| SEC industry code | Pharmaceutical Preparations |
| Business address | Beijing, China |
| Incorporated in | Cayman Islands |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | States substantial doubt about continuing as a going concern. "These factors raise substantial doubt about our ability to continue as a going concern within a reasonable period of time, which is considered to be one year from the issuance date of the annual report for the year ended December 31, 2025." | 20-F 2026-05-15 |
| Cash and burn | $5.6M cash; operating cash flow -$5.2M a quarter. | Report 2025-12-31 |
| Shares outstanding | 20,555,873 (2025-12-31); 15,492,581 a year earlier; 13,457,625 three years earlier. the newest SEC cover-page count is from 2025-12-31; shares issued since then are not in these figures. | Cover page 2025-12-31 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Delisting | 25-NSE filed | 25-NSE 2026-06-23 |
| Auditor | KPMG Huazhen LLP, Beijing, China | PCAOB Form AP 2026-06-02 |
| Late filings, 12 months | 1 NT notice | NT 20-F 2026-04-21 |
| Insider trades, 12 months | Bought $0, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Annual results
| Fiscal year | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| FY 2025 2025-12-31 | $20.7M | -$48.1M | -$20.8M | $5.6M | $19.2M | $20.7M | 20-F 2026-05-15 |
| FY 2024 2024-12-31 | $28.5M | -$39.3M | -$29.2M | $13.5M | $18.4M | $28.5M | 20-F 2026-05-15 |
| FY 2023 2023-12-31 | $33.9M | -$27.0M | -$20.0M | $17.1M | $18.9M | $33.9M | 20-F 2026-05-15 |
| FY 2022 2022-12-31 | $43.1M | -$41.0M | -$21.1M | $47.1M | No debt tags | $43.1M | 20-F 2025-03-31 |
| FY 2021 2021-12-31 | $30.2M | -$36.7M | -$26.8M | $38.7M | No debt tags | $30.2M | 20-F 2024-03-28 |
| FY 2020 2020-12-31 | $15.1M | -$48.3M | -$25.9M | Not filed | No debt tags | $15.1M | 20-F 2023-04-26 |
From SEC XBRL company facts (annual reports only: 20-F or 40-F). Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2025-04-01 |
| Latest annual report | 20-F | 2026-05-15 |
| Latest quarterly / interim | 6-K | 2026-09-02 |
Source: SEC EDGAR submissions feed, 157 recent filings. All filings on EDGAR.
The full dossier has every filing, quarterly and annual financials, the health record and a price chart.
Open the full dossier